Logo image of ATXS

ASTRIA THERAPEUTICS INC (ATXS) Stock Fundamental Analysis

USA - NASDAQ:ATXS - US04635X1028 - Common Stock

7.52 USD
+0.24 (+3.3%)
Last: 10/1/2025, 11:53:27 AM
Fundamental Rating

3

ATXS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. While ATXS has a great health rating, there are worries on its profitability. ATXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATXS has reported negative net income.
ATXS had a negative operating cash flow in the past year.
In the past 5 years ATXS always reported negative net income.
In the past 5 years ATXS always reported negative operating cash flow.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of ATXS (-41.47%) is comparable to the rest of the industry.
With a decent Return On Equity value of -44.88%, ATXS is doing good in the industry, outperforming 69.03% of the companies in the same industry.
Industry RankSector Rank
ROA -41.47%
ROE -44.88%
ROIC N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ATXS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

ATXS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATXS has been increased compared to 5 years ago.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 7.36 indicates that ATXS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.36, ATXS belongs to the top of the industry, outperforming 80.78% of the companies in the same industry.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.36
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 14.89 indicates that ATXS has no problem at all paying its short term obligations.
ATXS has a better Current ratio (14.89) than 89.55% of its industry peers.
ATXS has a Quick Ratio of 14.89. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
ATXS's Quick ratio of 14.89 is amongst the best of the industry. ATXS outperforms 89.55% of its industry peers.
Industry RankSector Rank
Current Ratio 14.89
Quick Ratio 14.89
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ATXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.63%, which is quite impressive.
EPS 1Y (TTM)25.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ATXS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-48.27%
EPS Next 2Y-26.29%
EPS Next 3Y-17.11%
EPS Next 5Y12.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ATXS's earnings are expected to decrease with -17.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.29%
EPS Next 3Y-17.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (10/1/2025, 11:53:27 AM)

7.52

+0.24 (+3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners90.92%
Inst Owner Change-1.29%
Ins Owners0.49%
Ins Owner Change0%
Market Cap424.35M
Analysts85.33
Price Target30.47 (305.19%)
Short Float %5.92%
Short Ratio9.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.06%
Min EPS beat(2)-18.75%
Max EPS beat(2)4.64%
EPS beat(4)3
Avg EPS beat(4)11.2%
Min EPS beat(4)-18.75%
Max EPS beat(4)56.57%
EPS beat(8)3
Avg EPS beat(8)-1.53%
EPS beat(12)7
Avg EPS beat(12)2.83%
EPS beat(16)9
Avg EPS beat(16)-94.96%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.84%
PT rev (3m)2.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.19%
EPS NY rev (1m)2.28%
EPS NY rev (3m)3.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)24.24%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0
BVpS4.62
TBVpS4.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.47%
ROE -44.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.89
Quick Ratio 14.89
Altman-Z 7.36
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
EPS Next Y-48.27%
EPS Next 2Y-26.29%
EPS Next 3Y-17.11%
EPS Next 5Y12.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.43%
EBIT Next 3Y-20.11%
EBIT Next 5Y-16.07%
FCF growth 1Y-158.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.25%
OCF growth 3YN/A
OCF growth 5YN/A